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A B S T R A C T
Background
The contribution of low-penetrant susceptibility variants to cancer is not clear. With the aim
of searching for genetic factors that contribute to cancer at one or more sites in the body, we
have analyzed familial aggregation of cancer in extended families based on all cancer cases
diagnosed in Iceland over almost half a century.
Methods and Findings
We have estimated risk ratios (RRs) of cancer for first- and up to fifth-degree relatives both
within and between all types of cancers diagnosed in Iceland from 1955 to 2002 by linking
patient information from the Icelandic Cancer Registry to an extensive genealogical database,
containing all living Icelanders and most of their ancestors since the settlement of Iceland.
We evaluated the significance of the familial clustering for each relationship separately, all
relationships combined (first- to fifth-degree relatives) and for close (first- and second-degree)
and distant (third- to fifth-degree) relatives. Most cancer sites demonstrate a significantly
increased RR for the same cancer, beyond the nuclear family. Significantly increased familial
clustering between different cancer sites is also documented in both close and distant relatives.
Some of these associations have been suggested previously but others not.
Conclusion
We conclude that genetic factors are involved in the etiology of many cancers and that these
factors are in some cases shared by different cancer sites. However, a significantly increased RR
conferred upon mates of patients with cancer at some sites indicates that shared environment
or nonrandom mating for certain risk factors also play a role in the familial clustering of cancer.
Our results indicate that cancer is a complex, often non-site-specific disease for which increased
risk extends beyond the nuclear family.
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Introduction
Highly penetrant susceptibility variants explain only a
small fraction of the genetics of all cancer cases. As an
example, mutations in the BRCA1 and BRCA2 genes account
for around 2%–3% of all breast cancer cases [1,2], although
more prevalent founder mutations in these genes can explain
up to about 10% of the disease in some populations [3,4,5,6,7].
However, the role of genetics in the remaining breast cancer
cases and the majority of other cancers is not clear.
Family studies have given insight into the contribution of
genetic and environmental factors to the etiology of cancer.
Case-control, registry- and population-based studies have
evaluated familial clustering using either risk ratio (RR)
estimations for relatives of cancer patients, or kinship
coefficient (KC) estimations for cancer patients. The largest
of these studies, utilizing either the Utah Population and
Cancer Registry Database or the Swedish Family-Cancer
Database, have demonstrated excess familial clustering at
practically all cancer sites in the body [8,9,10,11,12]. Most of
these studies have been able to evaluate familial clustering
only within the nuclear family, thus making it more difficult
to separate the roles of shared environmental and genetic
factors in the familial aggregation of cancers. However, in one
of these studies [12], in which familial clustering was evaluated
for more distant relatives, significant clustering outside the
nuclear family was demonstrated for a number of cancer sites.
Extended familial clustering has also been reported in studies
of individual cancers [13,14,15,16,17,18,19,20,21,22].
Twin studies have also evaluated the role of genes versus
environment in cancer susceptibility. The largest study
involved close to 45,000 twins from Denmark, Sweden, and
Finland where the RR of same type of cancer was calculated
for individuals with affected twins and compared to those
without an affected twin [23]. The authors concluded that for
the majority of cancer sites only a limited part of the risk
could be explained by heritable factors. Exceptions to this
were cancers of the prostate, colon and breast.
In addition to well documented familial clustering for the
majority of individual cancers, aggregation of different types
of cancers in families has also been observed. Reports have
been published on the results of systematic analysis of the
aggregation of different cancers using the Utah Population
and Cancer Registry Database [24,25]. In addition to
demonstrating excess familial clustering for most cancer
sites, these studies also indicate that an excess is also shared
by different cancer sites. In these studies, cancer clustering
was evaluated either by calculating the RR for first-degree
relatives or KC between different cancer sites. While distant
relationships contributed to the overall calculation of KC,
their contributions were not evaluated separately in the
studies between cancer sites, hence making it more difficult
to separate the effects of genetic and environmental factors
in these studies.
We have studied a registry of all cancer cases diagnosed in
Iceland from 1 January 1955 to 31 December 2002, with the
aim of searching for evidence of genetic factors both at
individual cancer sites and those shared by different sites. By
cross-referencing cancer prevalence in relatives of cases with
the aid of a comprehensive nationwide genealogy database,
we have estimated RR separately for first- to fifth-degree
relatives of all cancer patients diagnosed in Iceland over 48 y.
We demonstrate here an increased cancer risk in relatives
outside the nuclear family (third- to fifth-degree relatives) for
many cancer sites. These relatives share significant genetic
makeup but are less likely to share environmental factors
beyond those shared by the general population, indicating
that genetic factors may be involved. By applying the analysis
across different cancer sites we also demonstrate shared
familiality between certain cancer sites both in close and
distant relatives. These results suggest that cancer can be
considered a broad phenotype with shared genetic factors
crossing different cancer sites. That is, the difference between
cancers at various sites may in part be the consequence of
variable expressivity of the same cancer-predisposing genes.
Methods
This study was approved by the National Bioethics
Committee of Iceland, the Data Protection Authority of
Iceland, and the Icelandic Cancer Society. All names of
patients listed in the Icelandic Cancer Registry (ICR) and the
genealogic database were encrypted through a process
approved by the National Bioethics Committee and the Data
Protection Authority before being analyzed [26].
Cancer Registry
The ICR of the Icelandic Cancer Society is a carefully
constructed database containing practically complete records
of all cancer cases diagnosed in Iceland after 1 January 1955
[27]. Records are received at the ICR from all hospitals in the
country that treat cancer patients, and the very few not listed
are individuals who are diagnosed while living abroad.
Furthermore, the records are verified by a continuous
interaction between the ICR and Icelandic hospitals and
clinicians. Approximately 95% of cases are histologically
verified [28]. In the present study we used International
Classification of Disease version 10 codes as the basis for
defining phenotypes. A total of 81 unique phenotypes (sites)
were analyzed. In this paper we present data from 27 sites
with more than 200 cases each (Table 1). For the 48 years (1
January 1955 to 31 December 2002) a total of 32,534
individuals were found in our genealogy database. Cancer
incidence in Iceland is comparable to the Nordic countries of
Europe and is detailed in [27].
Genealogic Database
deCODE Genetics has built a computerized genealogy
database of more than 687,500 individuals [29,30]. The names
of all 288,000 Icelanders currently alive and a large
proportion of all Icelanders who have ever lived in the
country are in the database. The genealogy of the entered
individuals is recorded from multiple sources including
church records and censuses from previous centuries and,
more recently, from published genealogy books. The geneal-
ogy database is quite complete from the 18th century on, thus
allowing quite distant relationships to be traced accurately.
Mates are defined as individuals of the opposite sex who
have one or more children in common, regardless of marital
status.
Calculations of RRs
The RR for relatives is a measure of the risk of disease for a
relative of an affected person compared to the risk in the
population as a whole. More precisely, for a given relation-
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ship the RR for disease B in the relatives of probands with
disease A is defined as
RR ¼ PðRBjPAÞ
PðRBÞ ; ð1Þ
where PA denotes the event that the proband is affected with
disease A, and RB denotes the event that the relative is
affected with disease B. Note that disease A and disease B can
be the same in this definition which applies when estimating
RR at individual cancer sites. Using Bayes’ rule it can be
shown that for symmetric relationships, RR is the same if the
roles of A and B are switched, i.e., the RR for disease A in the
relatives of probands with disease B is the same as the
described above. In this study we always chose the less
common phenotype as the proband when estimating RR.
A basic underlying assumption in our estimation of RR is
that of conditional independence of ascertainment, or
censoring, (ORB and OPA are the events that the relative and
proband are observed with diseases A and B, respectively):
PðORB;OPAjPA;RBÞ ¼ PðORBjRBÞPðOPAjPAÞ: ð2Þ
Some form of this assumption is used by most methods
estimating RR [31].
Obtaining valid estimates of the RR is not always
straightforward, since the method of ascertainment of
affected cases critically affects the estimation, and inappro-
priate estimators can lead to bias or inflated estimates [32].
The use of a nationwide registry of patients covering close to
five decades decreases much of the potential sampling bias.
However, the ascertainment of the ICR depends on the year
of birth of individuals. This dependence needs to be
addressed when estimating the RR.
The approach chosen here is to estimate the RR for a
number of subpopulations, where prevalence is reasonably
constant, and combine them into a single estimate of RR for
the full population. Let r be the number of relatives of
probands, counting multiple times individuals who are
relatives of multiple probands [33], let a be the number of
relatives of probands that are affected (again possibly
counting the same individual more than once), let n be the
size of the population, and finally let x be the number of
affected individuals in the population. If P(RB) and P(RB j PA)
can reasonably be assumed to be constant in the population,
then x/n and a/r, respectively, are estimates of these proba-
bilities. Given these estimates, RR is consistently estimated by
a=r
x=n
: ð3Þ
Assuming the population can be split into N subpopula-
tions, such that within each subpopulation P(RB) and P(RB j
PA) can be assumed to be constant, although they may vary
between subpopulations, and assuming furthermore that RR
is the same in all the subpopulations, then the RR is
consistently estimated by a convex combination of the
estimates for the subpopulations. We selected weights for
the combination such that the efficiency of the estimator was
at maximum for RR equal to one. Making the simplifying
assumption that the relatives are independent (while this
assumption is not entirely correct, it affects only efficiency,
not validity), the optimal weight for group j is
wj ¼
xjrj
nj  xj ð4Þ
(this is the inverse of the variance of the estimate for RR in
subpopulation j), where a, r, x, and n are defined as above,
restricted to the subpopulation j. Note that probands are not
restricted to the subpopulation. Given these weights, our
estimate of RR is
XN
j¼1
wj
aj=rj
xj=nj
XN
j¼1
wj
¼
XN
j¼1
ajnj
nj  xj
XN
j¼1
rjxj
nj  xj
: ð5Þ
In this study, the most relevant variations in P(RB) and
P(RB j PA) stem from time-dependent censoring of affected
status and sex-specific differences. Hence, we have stratified
the population so that j runs over groups of people of the
same sex and born in the same 5-y periods. For a fixed year-
of-birth stratum, there is censoring of affected status (missing
data) based on year of onset because of the fact that records
cover only the period 1955–2002. Our approach is designed
to address this type of missing data. As an example of the
stratification, the breast cancer patients in our analysis were
born in the years 1865 to 1970 (5-y strata), yielding 35
subpopulations, 22 for female patients, but only 13 for male,
as this cancer is rare for males.
To assess the significance of the RR obtained for a given
group of patients, we compared their observed values with
the RR computed for up to 100,000 independently drawn and
matched groups of control individuals. Each patient was
matched to a single control individual in each control group.
The control individuals were drawn at random from the
genealogic database with the conditions that they had the
same year of birth, the same sex, and the same number of
ancestors recorded in the database at five generations back as
the matched patients. Empirical p values can be calculated
using the control groups; thus, a p value of 0.05 for the RR
would indicate that 5% of the matched control groups had
values as large as or larger than that for the patient’s relatives
or mates. The number of control groups required to obtain a
fixed accuracy of the empirical p values is inversely propor-
tional to the p value. We therefore selected the number of
control groups generated adaptively up to a maximum of
100,000. When none of the values computed for the
maximum number of control groups were larger than the
observed value for the patient’s relatives and mates, we report
the p value as being less than 0.00001. Using a variance-
stabilizing square-root transform, an approximate confidence
interval may be constructed based on the distribution of RR
for control groups [33].
As another test for significance of RR between cancer sites,
we used combined estimators for risk in relatives of degree 1
and 2 together, degrees 3, 4, and 5 together, and degrees 1
through 5 together. If RRd is the RR for relatives of degree d,
then RRd  1 is known to decrease proportional to 2d as d
increases for a monogenetic single variant or additive disease
models, and faster for more complex disease models [34].
With the estimate of RRd denoted by RRd
^
, we then chose a
test statistic of the form
X
d
wd
ðRRd
^ 1Þ
2d
; ð6Þ
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with d summed over the relevant degrees. For RRd close to
one, the variance of the estimate RRd
^
is inversely pro-
portional to the number of relatives of degree d for the
proband. Based on the Icelandic genealogy for the cancers
being studied here, the number of relatives is proportional to
cd, where the value of c quantifies how the number of relatives
grows with each degree of relatedness to the proband. This
factor c varies only slightly between cancers and is on average
2.46. Minimizing the variance of the test statistic in equation
6 with respect to the weights yields the statistic
X
d
1:23dðRRd
^ 1Þ: ð7Þ
As above, the choice of weights and the form of the statistic
affects only power, not validity. To assess significance, the
observed value of the statistic was compared to its value for
multiple matched control groups as described above.
Although our evaluations of familial clustering, for both
close and distant relatives, are based on RR, an alternative
approach based on comparing KCs among patients and
among controls exists [12,24,25]. The two approaches are
closely related, and our choice was made in part because
relative risk is a less technical concept and its application to
genetic counseling more direct. Also, the relationship
between relative risk and the power to map disease genes
by linkage analysis has been thoroughly investigated [34,35].
Results
We have studied the familial clustering of cancer by
estimating RR for first- and up to fifth-degree relatives both
within and between all cancer sites. Here we present results
for 27 sites that contain 200 or more cancer cases each, based
on International Classification of Disease version 10 codes.
These 27 sites represent 89% of all cancer cases in the ICR.
Risk Estimations for Cancer at Same Site
A significantly increased RR to first-degree relatives of
patients with cancer was seen for 22 of the 27 cancer sites
(Table 1). Among the statistically significant RRs, the highest
estimates were for lymphoid leukemia, Hodgkin’s disease, and
cancer of the thyroid, meninges, lip, testis, and larynx (RR
above three). These cancers, except for thyroid cancer, were
among the least prevalent sites (200–400 cases), as reflected in
the large standard deviation of the RR estimates (Table 1).
First-degree relatives of individuals with breast, lung, kidney,
pancreatic, ovarian, and esophageal cancer and multiple
myeloma, had between 2- and 3-fold increased risk of
developing the same cancer.
The medians of the estimated RR values for the 27 sites in
first- to fifth-degree relatives were 2.00, 1.32, 1.21, 1.10, and
1.04, respectively.
Combined p-values incorporating the increased risk for
first- to fifth-degree relatives identified 21 sites being
significant at a nominal level of 0.05. Sixteen of those sites
remained significant after Bonferroni adjustment for the 27
individual tests (p value , 0.00185) (Table 1). To discriminate
between familial clustering in close and distant relatives,
combined p values were also calculated for first- and second-
degree relatives on one hand and for third- to fifth-degree
relatives on the other hand (Table 1). Fourteen sites were
nominally significant for the distant relationships (third- to
fifth-degree relatives) of which eight were significant after
Bonferroni adjustment. These eight sites were all within the
group of 16 sites demonstrating significant familial clustering
in all relationships.
The RR for developing cancer at the same site was also
estimated for mates of cancer patients at 22 out of the 27
individual sites. The remaining five sites are sex-specific and
calculations thus not applicable. For seven rare cancer sites,
affected mates were not observed, corresponding to a RR of
zero. Only lung, stomach, and colon cancer were character-
ized by significantly increased RR values in mates (Table 1).
Risk Estimations between Cancer Sites
We calculated RR between all cancer sites for first- and up
to fifth-degree relatives and mates (results for the 27 largest
sites are shown in Table S1). As done for the individual cancer
sites, p values were calculated for all (first- to fifth-degree),
close (first- and second-degree), and distant (third- to fifth-
degree) relationships. Figure 1 shows a diagram representing
20 pairs of cancer sites that associate with a combined p value,
significant at a level of 1 3 104, for first- to fifth-degree
relationships. This level was significant at the 0.05 level after
Bonferroni adjustment for the 351 tests (number of unique
pairs of cancers). The strength of the distant familiality (i.e.,
the p value for third- to fifth-degree relatives) between these
pairs of cancers is represented by the thickness of the lines
joining sites in Figure 1.
In total, 17 cancer sites were involved in 20 significant pairs
of sites (Figure 1). Stomach and prostate cancer were involved
in most pairs, seven and six pairs, respectively, followed by
colon, ovarian, and cervical cancer, each involved in three
pairs. The estimated RRs for the 20 pairs are between 1.1 and
1.7 for first-degree relatives and between 1.1 and 1.5 for
second-degree relatives (Figure 1; Table S1). The highest RRs
in first-degree relatives between cancer sites were seen for
esophagus–cervix, with a RR of 1.74, pancreas–ovary, with a
RR of 1.66, and colon–rectum, with a RR of 1.64.
All of the 20 pairs shown in Figure 1 were nominally
significant (p value , 0.05) for distant relationships, of which
nine were significant at the 0.001 level. In the latter group,
prostate, rectum, stomach, and cervical cancers each ap-
peared in two pairs, and colon cancer in three.
Discussion
In this study we have comprehensively analyzed familial
aggregation of cancer cases in a whole nation, both within and
between pairs of cancer sites. The completeness of our
genealogy database allows us to accurately trace distant
relationships, which we believe is unique to this study. Linking
the ICR to our nationwide genealogy database thus has made
it possible to uncover distant familial connections between
cancer cases, and reach beyond shared environmental factors
to identify individual and combined cancer sites with the
strongest genetic influences. Furthermore, even though the
genetic effect decreases with more distant relationships, the
sample sizes used to estimate familiality are dramatically
larger for the distant relationships than for the closer ones.
This compensates to some extent for the lower effect and adds
considerable statistical power to the study.
In this paper we restrict the presentation and discussion to
the most significant findings. However, we provide results for
all pairs of 27 cancer sites in Table S1, as a resource for other
researchers interested in the familiality of specific cancers.
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The largest population-based studies reported to date,
evaluating familial clustering within the same cancer site, are
from Utah and Sweden [8,9,10]. These studies report RR
values for first-degree relatives [36] that are comparable to
those presented here for first-degree relatives. For example,
the median RRs for the occurrence of the same cancer in
first-degree relatives were 2.15, 1.86, and 2.00 for the Utah,
the Sweden, and our study, respectively. Also, RR values in
first-degree relatives ranged between 1.5 and 3.0 for the
majority of sites, i.e., 69%, 82%, and 60%, in Utah, Sweden,
and this study, respectively.
As seen in Utah and Sweden, high RR values were found in
this study for multiple myeloma, lymphoid leukemia, and
thyroid, testicular, and laryngeal cancer. The RR for thyroid
cancer in first-degree relatives was much higher in Utah and
Sweden (8.48 and 9.51) than in Iceland (3.02). One possible
explanation of the lower RR may be the high incidence of
thyroid cancer in Iceland, due to an excess of the papillary
subtype [18,37], which is not a part of the multiple endocrine
neoplasia syndromes.
The cancer sites showing the highest RR for first-degree
relatives tend to be among the rarer sites. There are two
potential reasons why rare tumors tend to show higher RRs
than common cancers. Being common, the baseline frequency
is not low and that creates a bound on how large the RR can be.
Also, common cancers are expected to be genetically complex,
whereas it is more likely for a rare tumor to be closer to a
Mendelian trait, caused by rare alleles with high penetrances.
Most individual cancer sites, or 16 out of the 27 studied
here, showed familiality as evidenced by significant p values
(after adjustment for multiple testing) for the combined
group of first- to fifth-degree relatives. Furthermore, eight of
these 16 sites remained significant even after exclusion of the
first- and second-degree relatives (after adjustment for
multiple testing). The majority of the 16 significant cancer
sites are among the sites of the most prevalent cancers,
indicating that we may lack power to detect extended
familiality for the less prevalent cancer sites. Indeed the
median number of cases per cancer site was 943 for the 16
significant sites compared to 342 for the non-significant sites.
Nevertheless, significant familial clustering (first- to fifth-
degree relatives) is seen for some of the less prevalent sites,
i.e., lymphoid leukemia and esophagus and meningeal cancer.
The largest cancer twin study reported to date [23]
documented significant heritability of prostate (42%), color-
ectal (35%), and breast cancer (27%) and provided suggestive
evidence for limited heritability of leukemia and stomach,
lung, pancreas, ovarian, and bladder cancer. All of these
cancer sites showed significant familial clustering in our
study. However, when the analysis was restricted to distant
relatives, lymphoid leukemia, pancreatic, and ovarian cancer
were no longer significant. Although close to 45,000 pairs of
twins were included in the study (of which 10,803 had been
diagnosed with cancer), the study clearly lacked statistical
power to detect the effects of heritable factors for the less
prevalent cancer sites.
A significantly increased risk of the same cancer was seen in
mates only for individuals diagnosed with stomach, lung, or
colon cancer. These results are in accordance with previous
reports, including Swedish population-based studies, except
for colon cancer [38,39,40,41]. Environmental factors in adult
life (including lifestyle and infections) or nonrandom mating
could explain the higher risk of these cancer types in mates.
The RR was not significant or not observed in mates for other
sites.
We also assessed the significance of familial clustering
Figure 1. A Schematic Representation of
Cancer Pairs Demonstrating Significant
Familial Aggregation
Cancer pairs that demonstrate signifi-
cant familial co-clustering (first- to fifth-
degree relatives) at the 0.05 level after
adjustment for multiple testing (nominal
p value , 1 3 104) are joined by lines.
The thickness of the lines joining the
pairs are based on nominal p values
corresponding to the significance of the
familiality in distant relatives (third to
fifth degree): bold, p  0.001; solid, p 
0.01; and dashed, p  0.05. The number
on the lines joining each pair indicates
the cross-cancer RR in first-degree rela-
tives. Shaded ovals correspond to indi-
vidual cancer sites that were significant
for the combined group of first- to fifth-
degree relatives at the 0.05 level after
Bonferroni adjustment (see Table 1).
DOI: 10.1371/journal.pmed.0010065.g001
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between cancer sites by calculating combined p values
corresponding to the increased risk for first- to fifth-degree
relationships. With this method, we detected 17 cancers that
linked into 20 pairs of sites that were significant after
adjustment for multiple testing. Stomach and prostate cancer
appearedmore frequently in the pairs than other cancer types,
followed by colon, ovarian, and cervical cancer. We emphasize
again, as with the same-cancer calculations, that we might lack
power to connect rare cancers to other cancer sites. This
possibility is highlighted by the fact that the 17 cancers in the
significant pairs are the most prevalent cancer sites in Iceland.
Some connections seen here between cancer sites may be
partly explained by known high-risk genes involved in
heritable syndromes. Thus, mutations in genes associated
with hereditary nonpolyposis colorectal cancers could ex-
plain a part of the risk shared between stomach, colon, rectal,
and endometrial cancer, and possibly brain and ovarian
cancer [42,43]. In a similar manner, mutations in BRCA1 and
BRCA2may explain in part the cluster seen between prostate,
breast, ovarian, and possibly pancreatic cancer [20,44,45,46].
Other known but even rarer cancer syndromes are likely to
explain only a handful of cases.
Undiscovered genetic factors could contribute to some
connections seenhere to amuchgreater extent than the known
susceptibility factors. Although these could include unknown
high-risk susceptibility genes, they are more likely multiple
genetic variants, each conferring small to moderate risk.
Familial clusters were identified between cancer sites, both
in close and distant relatives, that do not correspond to
known cancer syndromes. These include lung, esophageal,
cervical, and stomach cancer, which, interestingly, have been
associated with environmental rather than genetic factors.
One explanation for this excess familiality between these
cancer sites is an interaction of genetic susceptibility factors
with environmental carcinogens (e.g., tobacco and diet) or
infectious agents. Thus, the same environmental factor could
interact with the same genetic susceptibility factor or factors
to induce different cancers (i.e., smoking in lung and cervical
cancer). Alternatively, different environmental factors could
interact with the same genetic susceptibility factor or factors
to increase the risk for different cancers (i.e., smoking in lung
cancer and human papilloma virus in cervical cancer).
Hormone-related cancers form another risk cluster. Thus,
shared genetic susceptibility factors could directly influence
the hormonal metabolism to induce breast, prostate, thyroid,
or ovarian cancer in carriers. Alternatively, shared genetic
factors could interact with dietary factors to induce aggre-
gation of cancers at these sites in related individuals. A
significantly increased risk of breast, prostate, cervical, and
non-melanoma skin cancer was recently reported in first-
degree relatives of early-onset breast cancer patients from
Sweden that tested negative for BRCA1 and BRCA2mutations
[47]. Our data support the notion that unknown susceptibility
variants that increase the risk of breast and prostate cancer
and melanoma remain to be characterized.
Twomore groups of cancers with shared risk were identified
that each include sites that share the same developmental
progenitors: the prostate, kidney, and bladder are sites derived
from the nephrogenic ridge while colon, rectum, and stomach
are derived from the primitive gut tube. Therefore, the sites in
each group may share risk alleles that regulate embryonic
development, which can later play a role in oncogenesis.
Interestingly, three cancer sites/types, non-melanoma skin,
brain, and melanoma, that do not have significant same-
cancer familial clustering demonstrate significant cross-
cancer familial clustering with more prevalent cancer sites,
i.e., rectum, stomach, and kidney cancers, respectively.
Previous reports systematically evaluating the significance
of co-clustering of cancer pairs in families have utilized the
Utah Population Database. In these studies lip and prostate
cancers appear to associate most frequently with other cancer
sites. The same is true for prostate cancer in our study,
whereas lip cancer does not significantly associate with any
other cancer sites. This can at least in part be explained by the
difference in age-standardized incidence rates for lip cancer
in Iceland and Utah (Iceland 1.1 and Utah 2.4) [48]. In contrast,
stomach cancer associates with seven other cancer sites out of
the 20 significant pairs in our study, but only three other sites
in the Utah study. Of the 20 cancer pairs that significantly
associate in our study, eight concur with the Utah studies.
Because the increased cross-site RR extends beyond the
nuclear family, shared genetic factors may contribute to the
risk of more than one cancer type. This suggests that cancer
could be considered a broad phenotype with shared genetic
factors across cancer sites. Therefore cancer should in certain
cases be studied in a broader context than previously done.
Combining multiple cancers that show increased cross-site
RR may serve to increase the power of linkage and case-
control studies. Our results also have implications for genetic
counseling and imply that the focus of attention should
broaden to the history of multiple cancer types in relatives
within and outside the nuclear family. These results also
suggest the utility of comparing expression profiles and in
vitro biological processes across the cancers that we have
identified as sharing genetic risk. The isolation of cancer
predisposition genes with broad effects may define new rate-
limiting pathways that can be used to search for drug targets
for a more focused treatment with fewer side effects but with
utility across multiple cancers.
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Patient Summary
Background Although a few cancers have a fairly simple genetic cause,
most, especially the most common cancers, do not, and what makes one
person rather than another develop cancer is not clear. One way of
trying to work out how much genes rather than environment contribute
to disease is to study large populations. One such population is the
Icelandic nation: not only is detailed health information about individuals
available, including information on cancer, but also very good
genealogical information and a substantial amount of genetic data.
What Did the Study Find? Researchers examined all cancer records
dating back to 1955 and then analyzed the chances of relatives and
mates of these patients having cancer. They found that some cancers,
especially rare ones, had a higher than baseline chance of occurring in
relatives, but so did many common cancers, and for some cancers, the
higher chances extended to quite distant relatives. In addition, the risk
sometimes involved different cancer types.
What Does the Study Mean for Patients? Even for the highest risk
cancers, the absolute increased risk for relatives remains very small. In
addition, despite the large numbers of patients studied, the numbers of
cancer cases are still not large enough to be completely certain of the
results, apart from very common cancers, which had the lowest chance
of occurring in relatives. So these results will not help doctors much at
the present time in telling an individual patient what their risk is of
getting cancer if a relative has it—but they will be useful for other
researchers in knowing how to plan future studies to look at the
underlying causes of cancer.
Where Can I Get More Information?
Icelandic Cancer Society: http://www.krabb.is/cancer/
The United States National Cancer Institute’s Cancer Information Service:
http://cis.nci.nih.gov/
CancerHelp UK, a free information service about cancer and cancer care:
http://www.cancerhelp.org.uk/
deCODE Genetics:http://www.decode.com
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